US 2025/0057884 A1 · Chimeric Antigen Receptor-T Cells Targeting HIV-Infected Cells

Abstract

One aspect of the present application relates to a recombinant cell comprising a chimeric antigen receptor and shRNA targeted to inhibit the life cycle of HIV. Another aspect of the present application relates to a chimeric antigen molecule, the extracellular region of which is from or comprising the extracellular region of human CD4 molecule, the transmembrane region of which is from or comprising the transmembrane domain of CD8α, and a recombinant cell comprising the above chimeric antigen molecule. The above recombinant cell can be used to treat HIV infection, and have stronger comprehensive killing efficacy, longer effective time, and less risk of causing cytokine storm in the environment of HIV infection.

Claims70

Dependent claims

A recombinant cell comprising the following functional structure:

1) a chimeric antigen receptor (CAR) or a nucleic acid coding therefor, wherein the CAR comprises an extracellular region, a transmembrane region and an intracellular region, wherein the extracellular region can specifically bind to the gp120 protein of HIV;
and
2) at least one shRNA or a nucleic acid coding therefor, wherein the shRNA targets one or more host genes or HIV genes involved in the HIV life cycle selected from the group consisting of NF-κB, CCR5, TSG101, CXCR4, P-TEFb, tat, rev, nef, env, LTR and gag.

A chimeric antigen receptor (CAR), comprising an extracellular region, a transmembrane region and an intracellular region, wherein the extracellular region is from or comprises the extracellular region of human CD4 molecule, and the transmembrane region is from or comprising the transmembrane domain of CD8α;

preferably, the chimeric antigen receptor further comprises a hinge region, and the extracellular region is connected to the transmembrane region by the hinge region;
preferably, the hinge region is from or comprises human Ig hinge region, GS linker, KIR2DS2 hinge, or the hinge region of CD8α, preferably the hinge region of CD8α;
preferably, the hinge region comprises the amino acid sequence of SEQ ID NO:
20 or comprises the amino acid sequence having at least 85% identity to the sequence of SEQ ID NO:
20.

2 more elements

Dependencies are inferred from the claim text.

Chimeric Antigen Receptor-T Cells Targeting HIV-Infected Cells

Life of this patent

Chimeric Antigen Receptor-T Cells Targeting HIV-Infected Cells

Life of this patent

Abstract

Claims70